OTCMKTS:GTBP GT Biopharma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GT Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.17 0.00 (-0.30 %) (As of 09/18/2020 08:10 PM ET) Add Compare Share Today's Range$0.17Now: $0.17▼$0.1750-Day Range$0.16MA: $0.18▼$0.2052-Week Range$0.07Now: $0.17▼$0.27Volume92,001 shsAverage Volume139,584 shsMarket Capitalization$12.36 millionP/E RatioN/ADividend YieldN/ABeta-0.38 ProfileChartCompetitorsEarningsInstitutional OwnershipHeadlinesShort InterestSocial Media GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms. The company develops immuno-oncology product candidates, including OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors; OXS-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate targeting CD33+ malignancies; OXS-C3550, a next-generation version of OXS-3550 containing a modified CD16 component; and OXS-1615, a single-chain fusion protein that targets epithelial tumors and CD133 positive solid tumors. It also develops central nervous system central nervous system, such as GTP-004, a fixed-dose combination tablet that has completed Phase I clinical trial for the treatment of the muscle weakness associated with myasthenia gravis; PainBrake, a patented formulation of carbamazepine to treat neuropathic pain; and GTP-011, a transdermal product for the prevention of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was founded in 1965 and is based in Westlake Village, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for GT Biopharma. Previous Next 2.3 Community Rank Outperform VotesGT Biopharma has received 96 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGT Biopharma has received 112 “underperform” votes. (Add your “underperform” vote.)Community SentimentGT Biopharma has received 53.85% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GT Biopharma and other stocks. Vote “Outperform” if you believe GTBP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GTBP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGT Biopharma does not currently pay a dividend.Dividend GrowthGT Biopharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GT Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.51% of the stock of GT Biopharma is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.46 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:GTBP Previous SymbolOTCMKTS:OXISD CUSIPN/A CIKN/A Webwww.gtbiopharma.com Phone800-304-9888Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.29) per share Price / Book-0.57Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-38,650,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-6,202.68%Miscellaneous Employees3 Outstanding Shares74,883,000Market Cap$12.36 million Next Earnings Date11/12/2020 (Estimated) OptionableNot Optionable $0.17 0.00 (-0.30 %) (As of 09/18/2020 08:10 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GTBP News and Ratings via Email Sign-up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. GT Biopharma (OTCMKTS:GTBP) Frequently Asked Questions How has GT Biopharma's stock been impacted by COVID-19? GT Biopharma's stock was trading at $0.1880 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GTBP stock has decreased by 12.2% and is now trading at $0.1650. View which stocks have been most impacted by COVID-19. When is GT Biopharma's next earnings date? GT Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for GT Biopharma. Are investors shorting GT Biopharma? GT Biopharma saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 13,000 shares, an increase of 20.4% from the August 15th total of 10,800 shares. Based on an average trading volume of 221,100 shares, the short-interest ratio is presently 0.1 days. View GT Biopharma's Short Interest. Who are some of GT Biopharma's key competitors? Some companies that are related to GT Biopharma include Cumberland Pharmaceuticals (CPIX), Vistagen Therapeutics (VTGN), ASLAN PHARMACEU/ADR (ASLN), Aptorum Group (APM), CohBar (CWBR), Helix Biopharma (HBPCF), Processa Pharmaceuticals (PCSA), Ceapro (CRPOF), Newron Pharmaceuticals (NWPHF), ProPhase Labs (PRPH), IMMURON LTD/S (IMRN), Pulmatrix (PULM), Oragenics (OGEN), Addex Therapeutics (ADDXF) and PDS Biotechnology (PDSB). View all competitors. What other stocks do shareholders of GT Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other GT Biopharma investors own include Cronos Group (CRON), Canopy Growth (CGC), Canopy Growth (WEED), Auxly Cannabis Group (CBWTF), KushCo (KSHB), Aurora Cannabis (ACBFF), Alibaba Group (BABA), Cara Therapeutics (CARA), PotNetwork (POTN) and American Cannabis (AMMJ). Who are GT Biopharma's key executives? GT Biopharma's management team includes the following people: Mr. Anthony J. Cataldo, Chairman of Directors, CEO & Pres (Age 67)Mr. Steven W. Weldon, CFO, Principal Accounting Officer & Director (Age 43) What is GT Biopharma's stock symbol? GT Biopharma trades on the OTCMKTS under the ticker symbol "GTBP." How do I buy shares of GT Biopharma? Shares of GTBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is GT Biopharma's stock price today? One share of GTBP stock can currently be purchased for approximately $0.17. How big of a company is GT Biopharma? GT Biopharma has a market capitalization of $12.36 million. GT Biopharma employs 3 workers across the globe. What is GT Biopharma's official website? The official website for GT Biopharma is www.gtbiopharma.com. How can I contact GT Biopharma? GT Biopharma's mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The company can be reached via phone at 800-304-9888 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
